stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Operating cash flow
Teva Pharmaceutical Industries Ltd.'s operating cash flow for fiscal 2025 was $1.6B, up 32.2% from $1.2B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.8B. Over the past ten years it has ranged from $748.0M (fiscal 2019) to $5.5B (fiscal 2015); the current reading is higher than 64% of that period. Teva Pharmaceutical Industries Ltd. ranks 5th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.6B | 32.24% |
| FY2024 | $1.2B | (8.85%) |
| FY2023 | $1.4B | (13.96%) |
| FY2022 | $1.6B | 99.25% |
| FY2021 | $798.0M | (34.37%) |
| FY2020 | $1.2B | 62.57% |
| FY2019 | $748.0M | (69.42%) |
| FY2018 | $2.4B | 9.93% |
| FY2017 | $2.2B | (57.42%) |
| FY2016 | $5.2B | (5.72%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $241.0M | (41.36%) |
| Jun 2026 | $411.0M | — |
| Mar 2026 | −$40.0M | — |
| Dec 2025 | $1.2B | 213.82% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $11.6B |
| HLN Haleon PLC Sponsored ADR compare | $4.8B |
| ZTS Zoetis Inc. compare | $2.8B |
| VTRS Viatris Inc. compare | $2.5B |
| TEVA Teva Pharmaceutical Industries Ltd. | $1.8B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement